Bayer, Evotec Alliances Create 'Virtual' Specialized Businesses With Finite Goals

On the sidelines of the BIO-Europe partnering conference, held in Cologne, Germany, Dr Joerg Moeller, head of development for Bayer's pharmaceuticals division, and Evotec CEO Dr Werner Lanthaler tell Scrip why their partnerships work and what challenges they have overcome to create short-term syndicated businesses with specific therapeutic focuses.

Bayer AG and Evotec AG have recently struck a second collaboration, this time in kidney disease, on the back of their successful discovery and development partnership looking at new drug candidates for women's health indications. Bayer's head of development for pharmaceuticals, Dr Joerg Moeller, and Evotec chief, Dr Werner Lanthaler, told Scrip more about their "modern" setup and how fixed project endings help to eradicate development bottlenecks.

In Oct. 2012 Bayer and Evotec entered into a five-year multi-target strategic alliance to identify three small molecule clinical candidates...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

25 Jul 2025

• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

24 Jul 2025

• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.